Norfolk, VIRGINIA2 Active Studies

Duchenne Muscular Dystrophy Clinical Trials in Norfolk, VIRGINIA

Find 2 actively recruiting duchenne muscular dystrophy clinical trials in Norfolk, VIRGINIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
90
Enrolling

Recruiting Duchenne Muscular Dystrophy Studies in Norfolk

About Duchenne Muscular Dystrophy Clinical Trials in Norfolk

Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. It is caused by mutations in the dystrophin gene. Treatment includes corticosteroids, gene therapies, and supportive care to maintain mobility and function.

There are currently 2 duchenne muscular dystrophy clinical trials recruiting participants in Norfolk, VIRGINIA. These studies are seeking a combined 90 participants. Research is being sponsored by Hoffmann-La Roche, Solid Biosciences Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Duchenne Muscular Dystrophy Clinical Trials in Norfolk — FAQ

Are there duchenne muscular dystrophy clinical trials in Norfolk?

Yes, there are 2 duchenne muscular dystrophy clinical trials currently recruiting in Norfolk, VIRGINIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Norfolk?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Norfolk research site will contact you about next steps.

Are clinical trials in Norfolk free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Norfolk studies also compensate for your time and travel.

What duchenne muscular dystrophy treatments are being tested?

The 2 active trials in Norfolk are testing new therapies including novel drugs, biologics, and treatment approaches for duchenne muscular dystrophy.

Data updated March 2, 2026 from ClinicalTrials.gov